WINDA DWI P., Dr. Nanang Munif Yasin, M.Pharm., Apt.; Dr ...

109

DAFTAR PUSTAKA

Adler, M.W., 1996. Perkembangan Epidemiologi, dalam: Petunjuk Penting AIDS

(ABC of AIDS). Penerbit Buku Kedokteran EGC, Jakarta.

Amin, J., Boyd, M.A., Kumarasamy, N., Moore, C.L., Losso, M.H., Nwizu, C.A.,

dkk., 2015. Raltegravir Non-Inferior to Nucleoside Based Regimens in

SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A

Randomised Open Label Study for the Treatment Of HIV-1 Infection. PLOS

ONE, 10: e0118228.

Anonim, 2007. 'Hasil Monitoring 25 RS Rujukan Pelayanan Kesehatan ODHA

Direktur Jenderal Pelayanan Medik Departemen Kesehatan RI', Yayasan

Mitra INTI. URL: http://www.mitrainti.org/?q=node/340 (diakses tanggal

6/2/2018).

Anonim, 2017. 'DynaMed Plus® The Next-generation , Evidence-based Clinical

Information Resource, Designed to Optimize Time to Answer', EBSCO.

URL: https://www.ebscohost.com/assets-ebrochures/DynaMed-Plus-

eBrochure.pdf?_ga=2.252662543.721294030.1525794474-

884887223.1525204792 (diakses tanggal 1/6/2018).

Arnedo, M., Alonso, E., Eisenberg, N., Ibanez, L., Ferreyra, C., Jaen, A., dkk.,

2012. Monitoring HIV Viral Load in Resource Limited Settings: Still a

Matter of Debate? PLoS ONE, 7: e47391.

Astuti, W. dan Rayasari, F., 2017. Pengalaman Seksual Pasangan Penderita HIV

dalam Mempertahankan Status HIV Negatif di RSPI Prof. Dr. Sulianti

Saroso. Indonesian Journal of Nursing Practices, 1: 32–43.

Bartlett, J. (Editor), 2012. CD4 Cell Count and the Risk of AIDS or Death in HIV-

Infected Adults on Combination Antiretroviral Therapy with a Suppressed

Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Medicine,

9: e1001194.

Barus, T., Anwar, Y., dan Ginting, D., 2017. Evaluasi Efek Samping Obat

Antiretroviral dan Penatalaksanaanya pada Pasien HIV/AIDS di Puskesmas

Kecamatan Penjaringan Jakarta Utara Periode Tahun 2013 – 2015. Social

Clinical Pharmacy Indonesia Journal, 2: 29–37.

Benn, P., Sauret-Jackson, V., Cartledge, J., Ruff, C., Sabin, C., Moyle, G., dkk.,

2009. Improvements in Cheek Volume in Lipoatrophic Individuals

Switching Away from Thymidine Nucleoside Reverse Transcriptase

Inhibitors. HIV Medicine, 10: 351–355.

Berrada, S., Mkandawire, T., Kamungoma-Dada, I., Njuho, P., Thipa, N., Pinini,

Z., dkk., 2013. 'What are The Reasons for Switching ART Patients to

Second-Line Regimen in Public Healthcare Settings in Gauteng? Submitted

to the US Agency for International Development by the Systems for

Improved Access to Pharmaceuticals and Services (SIAPS) Program', .

Management Sciences for Health, Arlington, VA.

Perbandingan Luaran Terapi Rejimen Antiretroviral Lini Kedua pada Pasien HIV/AIDSWINDA DWI P., Dr. Nanang Munif Yasin, M.Pharm., Apt.; Dr. Fita Rahmawati Sp.FRS.,Apt.Universitas Gadjah Mada, 2018 | Diunduh dari http://etd.repository.ugm.ac.id/

110

Besral, B., Utomo, B., dan Zani, A.P., 2004. Potensi Penyebaran HIV dari

Pengguna NAPZA Suntik ke Masyarakat Umum. Makara Kesehatan, 8:

53–58.

Bezabhe, W.M., Bereznicki, L.R., Chalmers, L., Gee, P., Kassie, D.M., Bimirew,

M.A., dkk., 2015. Adverse Drug Reactions and Clinical Outcomes in

Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study

From Ethiopia. Drug Safety, 38: 629–639.

Biewenga, J., Keung, C., Solanki, B., Natarajan, J., Leitz, G., Deleu, S., dkk., 2015.

Absence of QTc Prolongation with Domperidone: A Randomized, Double-

Blind, Placebo- and Positive-Controlled Thorough QT/QTc Study in

Healthy Volunteers: Clinical Pharmacology in Drug Development. Clinical

Pharmacology in Drug Development, 4: 41–48.

BNN, 2004. Biaya Ekonomi dan Sosial Penyalahgunaan Narkoba di Indonesia,

dalam: Himpunan Hasil Penelitian Badan Narkotika Nasional 2003 Dan

2004. Badan Narkotika Nasional, Jakarta.

Boettiger, D.C., Nguyen, V.K., Durier, N., Bui, H.V., Heng Sim, B.L., Azwa, I.,

dkk., 2015. Efficacy of Second-Line Antiretroviral Therapy Among People

Living With HIV/AIDS in Asia: Results From the TREAT Asia HIV

Observational Database. JAIDS Journal of Acquired Immune Deficiency

Syndromes, 68: 186–195.

Bor, J., Herbst, A.J., Newell, M.-L., dan Bärnighausen, T., 2013. Increases in Adult

Life Expectancy in Rural South Africa: Valuing the Scale-up of HIV

Treatment. Science, 339: 961–965.

Boyd, M.A., Moore, C.L., Molina, J.-M., Wood, R., Madero, J.S., Wolff, M., dkk.,

2015. Baseline HIV-1 Resistance, Virological Outcomes, and Emergent

Resistance in the SECOND-LINE Trial: an Exploratory Analysis. The

Lancet HIV, 2: e42–e51.

Bunupuradah, T., Chetchotisakd, P., Ananworanich, J., Munsakul, W.,

Jirajariyavej, S., Kantipong, P., dkk., 2012. A Randomized Comparison of

Second-Line Lopinavir/Ritonavir Monotherapy vs.

Tenofovir/Lamivudine/Lopinavir/Ritonavir in Patients Failing NNRTI-

Regimens: The HIV STAR Study. Antiviral Therapy, 17: 1351–1361.

Bunyamin, J., 2014. 'Association between Stavudin Administration with

Lipodystrophy and Dyslipidemia among HIV-infected Patients in Dr.

Kariadi Hospital Semarang', , Skripsi, S. Ked., . Universitas Diponegoro,

Semarang.

Castro, K.G., Ward, J.W., Slutsker, L., Buehler, J.W., Jaffe, H.W., dan Berkelman,

R.L., 1992. '1993 Revised Classification System for HIV Infection and

Expanded Surveillance Case Definition for AIDS Among Adolescents and

Adults', . URL:

https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm (diakses

tanggal 28/3/2018).

Chakravarty, J., Sundar, S., Chourasia, A., Singh, P.N., Kurle, S., Tripathy, S.P.,

dkk., 2015. Outcome of Patients on Second Line Antiretroviral Therapy

Under Programmatic Condition in India. BMC infectious diseases, 15: 517.


111

Charbonneau, D.H. dan James, L.N., 2018. DynaMed Plus®: An Evidence-Based

Clinical Reference Resource. Medical Reference Services Quarterly, 37:

168–176.

Chastain, D.B., Stover, K.R., dan Riche, D.M., 2017. Evidence-Based Review of

Statin Use in Patients with HIV on Antiretroviral Therapy. Journal of

Clinical & Translational Endocrinology, 8: 6–14.

Chauvin, B., Drouot, S., Barrail-Tran, A., dan Taburet, A.-M., 2013. Drug–Drug

Interactions between HMG-CoA Reductase Inhibitors (Statins) and

Antiviral Protease Inhibitors. Clinical Pharmacokinetics, 52: 815–831.

Chodidjah, S., Agustini, N., dan Ungsianik, T., 2004. Hubungan antara

Pengetahuan tentang HIV/AIDS dengan Perilaku Seksual Pranikah pada

Remaja. Jurnal Keperawatan Indonesia, 8: 50–53.

Ciaffi, L., Koulla-Shiro, S., Sawadogo, A., le Moing, V., Eymard-Duvernay, S.,

Izard, S., dkk., 2015. Efficacy and safety of three second-line antiretroviral

regimens in HIV-infected patients in Africa. AIDS (London, England), 29:

1473–1481.

Collier, D., Iwuji, C., Derache, A., de Oliveira, T., Okesola, N., Calmy, A., dkk.,

2017. Virological Outcomes of Second-line Protease Inhibitor-Based

Treatment for Human Immunodeficiency Virus Type 1 in a High-

Prevalence Rural South African Setting: A Competing-Risks Prospective

Cohort Analysis. Clinical Infectious Diseases: An Official Publication of

the Infectious Diseases Society of America, 64: 1006–1016.

Collins, I.J., Foster, C., Kahlert, C., Smit, C., Goodall, R., Marques, L., dkk., 2018.

Time to Switch to Second-line Antiretroviral Therapy in Children With

Human Immunodeficiency Virus in Europe and Thailand. Clinical

Infectious Diseases, 66: 594–603.

Curran, A. dan Ribera, E., 2011. From Old to New Nucleoside Reverse

Transcriptase Inhibitors: Changes in Body Fat Composition, Metabolic

Parameters and Mitochondrial Toxicity After the Switch from Thymidine

Analogs to Tenofovir or Abacavir. Expert Opinion on Drug Safety, 10: 389–

406.

Dahlan, M.S., 2014. Statistik Untuk Kedokteran Dan Kesehatan : Deskriptif,

Bivariat, Dan Multivariat Dilengkapi Aplikasi Menggunakan SPSS, Edisi

Keenam. ed. Epidemiologi Indonesia, Jakarta.

Damtie, D., Yismaw, G., Woldeyohannes, D., dan Anagaw, B., 2013. Common

Opportunistic Infections and Their CD4 Cell Correlates among HIV-

infected Patients Attending at Antiretroviral Therapy Clinic of Gondar

University Hospital, Northwest Ethiopia. BMC Research Notes, 6: 534.

Danion, F., Aguilar, C., Catherinot, E., Alanio, A., DeWolf, S., Lortholary, O., dkk.,

2015. Mucormycosis: New Developments into a Persistently Devastating

Infection. Seminars in Respiratory and Critical Care Medicine, 36: 692–

705.

De Luca, A., Sidumo, Z.J., Zanelli, G., Magid, N.A., Luhanga, R., Brambilla, D.,

dkk., 2017. Accumulation of HIV-1 Drug Resistance in Patients on a

Standard Thymidine Analogue-Based First Line Antiretroviral Therapy

After Virological Failure: Implications for the Activity of Next-Line


112

Regimens from a Longitudinal Study in Mozambique. BMC Infectious

Diseases, 17: 605.

de Waal, R., Cohen, K., dan Maartens, G., 2013. Systematic Review of

Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat

Gain, Is an Antiretroviral Adverse Drug Reaction. PLoS ONE, 8: e63623.

Decloedt, E.H., Maartens, G., Smith, P., Merry, C., Bango, F., dan McIlleron, H.,

2012. The Safety, Effectiveness, and Concentrations of Adjusted

Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based

Antitubercular Therapy. PLoS ONE, 7: e32173.

Delfraissy, J.-F., Flandre, P., Delaugerre, C., Ghosn, J., Horban, A., Girard, P.-M.,

dkk., 2008. Lopinavir/Ritonavir Monotherapy or Plus Zidovudine and

Lamivudine in Antiretroviral-Naive HIV-Infected Patients. AIDS, 22: 385–

393.

Depkes RI, 2004. Keputusan Menteri Kesehatan Republik Indonesia Tentang

Standar Pelayanan Farmasi Di Rumah Sakit. Departemen Kesehatan RI,

Jakarta.

Direktorat Bina Farmasi Komunitas dan Klinik, 2006. Pedoman Pelayanan

Kefarmasian Untuk Orang Dengan HIV/AIDS (ODHA). Direktorat Bina

Farmasi Komunitas dan Klinik, Ditjen Bina Kefarmasian dan Alat

Kesehatan, Departemen Kesehatan RI, Jakarta.

Ditjen PPM&PL, 2004. Pedoman Nasional Terapi Antiretroviral. Direktorat

Jenderal Pemberantasan Penyakit Menular dan Penyehatan Lingkungan,

Departemen Kesehatan RI, Jakarta.

Ditjen PP&PL, 2008. 'Statistik Kasus HIV/AIDS di Indonesia Dilaporkan Sampai

dengan Desember 2007', Yayasan Spiritia. URL:

http://www.spiritia.or.id/Stats/Statistik.php (diakses tanggal 4/2/2018).

Ditjen PP&PL, 2017. 'Statistik Kasus HIV/AIDS di Indonesia Dilaporkan Sampai

dengan Desember 2016', Yayasan Spiritia. URL:

http://www.spiritia.or.id/Stats/Statistik.php (diakses tanggal 4/2/2018).

Dooley, K.E., Flexner, C., dan Andrade, A.S., 2008. Drug Interactions Involving

Combination Antiretroviral Therapy and Other Anti‐Infective Agents:

Repercussions for Resource‐Limited Countries. The Journal of Infectious

Diseases, 198: 948–961.

Drugs.com, 2018. 'Drug Interaction Report', Drugs.com. URL:

https://www.drugs.com/interactions-check.php?drug_list=276-0,1096-

0,1484-0,1605-0,2012-0,2067-0,1863-15957&professional=1 (diakses

tanggal 12/3/2018).

Duval, X., Journot, V., Leport, C., Cheˆne, G., Dupon, M., Cuzin, L., dkk., 2004.

Incidence of and Risk Factors for Adverse Drug Reactions in a Prospective

Cohort of HIV-Infected Adults Initiating Protease Inhibitor–Containing

Therapy. Clinical Infectious Diseases, 39: 248–255.

Ehrenpreis, E.D., Roginsky, G., Alexoff, A., dan Smith, D.G., 2017. Domperidone

is Commonly Prescribed With QT-Interacting Drugs: Review of a

Community-based Practice and a Postmarketing Adverse Drug Event

Reporting Database. Journal of Clinical Gastroenterology, 51: 56–62.


113

Eluwa, G.I., Badru, T., dan Akpoigbe, K.J., 2012. Adverse Drug Reactions to

Antiretroviral Therapy (ARVs): Incidence, Type and Risk Factors in

Nigeria. BMC Clinical Pharmacology, 12: 1–9.

Epstein, F.H., Pantaleo, G., Graziosi, C., dan Fauci, A.S., 1993. The

Immunopathogenesis of Human Immunodeficiency Virus Infection. New

England Journal of Medicine, 328: 327–335.

Evans, S.R., Ellis, R.J., Chen, H., Yeh, T., Lee, A.J., Schifitto, G., dkk., 2011.

Peripheral Neuropathy in HIV: Prevalence and Risk Factors. AIDS, 25:

919–928.

Fairall, L.R., Bachmann, M.O., Louwagie, G.M.C., Vuuren, C. van, Chikobvu, P.,

Steyn, D., dkk., 2008. Effectiveness of Antiretroviral Treatment in a South

African Program, A Cohort Study. Archives of Internal Medicine, 168: 86.

Ferradini, L., Ouk, V., Segeral, O., Nouhin, J., Dulioust, A., Hak, C., dkk., 2011.

High Efficacy of Lopinavir/r-based Second-Line Antiretroviral Treatment

After 24 Months of Follow Up at ESTHER/Calmette Hospital in Phnom

Penh, Cambodia. Journal of the International AIDS Society, 14: 14.

Finkelstein, J.L., Gala, P., Rochford, R., Glesby, M.J., dan Mehta, S., 2015.

HIV/AIDS and Lipodystrophy: Implications for Clinical Management in

Resource-limited Settings. Journal of the International AIDS Society, 18:

1–22.

Fletcher, C.V. dan Kakuda, T.N., 2005. Human Immunodeficiency Virus Infection.

Dipiro, J.T., Talbert, R.I., Yee, G.C., Maatzke, A., Wells, B.G., Passey,

L.M., dalam: Pharmacotherapy: A Pathophysiologic Approach. Appleton

and Lange, Philadelphia.

Ford, N., Shubber, Z., Hill, A., Vitoria, M., Doherty, M., Mills, E.J., dkk., 2013.

Comparative Efficacy of Lamivudine and Emtricitabine: A Systematic

Review and Meta-Analysis of Randomized Trials. PLoS ONE, 8: e79981.

Gilks, C.F., Walker, A.S., Munderi, P., Kityo, C., Reid, A., Katabira, E., dkk., 2013.

A Single CD4 Test with 250 Cells/mm3 Threshold Predicts Viral

Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical

Criteria. PLoS ONE, 8: e57580.

Gunda, D.W., Kidenya, B.R., Mshana, S.E., Kilonzo, S.B., dan Mpondo, B.C.T.,

2017. Accuracy of WHO Immunological Criteria in Identifying Virological

Failure among HIV-infected Adults on First Line Antiretroviral Therapy in

Mwanza, North-western Tanzania. BMC Research Notes, 10: 1–5.

Haggblom, A., Santacatterina, M., Neogi, U., Gisslen, M., Hejdeman, B., Flamholc,

L., dkk., 2017. Effect of Therapy Switch on Time to Second-Line

Antiretroviral Treatment Failure in HIV-Infected Patients. PLOS ONE, 12:

e0180140.

Hakim, J.G., Thompson, J., Kityo, C., Hoppe, A., Kambugu, A., van Oosterhout,

J.J., dkk., 2017. Lopinavir Plus Nucleoside Reverse-Transcriptase

Inhibitors, Lopinavir Plus Raltegravir, or Lopinavir Monotherapy for

Second-Line Treatment of HIV (EARNEST): 144-Week Follow-up Results

from a Randomised Controlled Trial. The Lancet Infectious Diseases, 18:

47–57.


114

Han, Y., Li, Yijia, Xie, J., Qiu, Z., Li, Yanling, Song, X., dkk., 2015. Week 120

Efficacy of Tenofovir, Lamivudine, and Lopinavir/r-Based Second-Line

Antiretroviral Therapy in Treatment-Experienced HIV Patients. PLOS

ONE, 10: e0120705.

Hawkins, T., 2010. Understanding and Managing the Adverse Effects of

Antiretroviral Therapy. Antiviral Research, 85: 201–209.

Hidayati, N.R., Abdillah, S., dan Keban, S.A., 2016. Analisis Adverse Drug

Reactions Obat Antiretroviral pada Pengobatan Pasien HIV/AIDS di RSUD

Gunung Jati Cirebon Tahun 2013. Pharmaciana, 6: 79–88.

Hughes, C.A., Foisy, M., dan Tseng, A., 2010. Interactions Between Antifungal and

Antiretroviral Agents. Expert Opinion on Drug Safety, 9: 723–742.

Jamil, K.F., 2014. Profil Kadar CD4 terhadap Infeksi Oportunistik pada Penderita

Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

(HIV/AIDS) Di RSUD Dr. Zainoel Abidin Banda Aceh. Jurnal Kedokteran

Syiah Kuala, 14: 76–80.

Jensen-Fangel, S., 2004. The Effectiveness of Highly Active Antiretroviral Therapy

in HIV-Infected Patients. Dan Med Bull, 51: 371–92.

Johnston, V., Cohen, K., Wiesner, L., Morris, L., Ledwaba, J., Fielding, K.L., dkk.,

2014. Viral Suppression Following Switch to Second-line Antiretroviral

Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor

Resistance and Subtherapeutic Drug Concentrations Prior to Switch. The

Journal of Infectious Diseases, 209: 711–720.

Johnston, V., Fielding, K., Charalambous, S., Mampho, M., Churchyard, G.,

Phillips, A., dkk., 2012. Second-Line Antiretroviral Therapy in a Workplace

and Community-Based Treatment Programme in South Africa:

Determinants of Virological Outcome. PLoS ONE, 7: e36997.

Kemenkes RI, 2007. 'Keputusan Menteri Kesehatan Republik Indonesia tentang

Penetapan Lanjutan Rumah Sakit Rujukan bagi Orang Dengan HIV dan

AIDS (ODHA)', Komisi Penanggulangan AIDS. URL:

http://www.aidsindonesia.or.id/uploads/20130506131726.Skmenkes_Nom

or_760_MENKES_SK_VI_2007_Tentang_Penetapan_Lanjutan_Rumah_

Sakit_Rujukan_Bagi_Orang_Dengan_HIV_dan_AIDS_ODHA.pdf

(diakses tanggal 6/2/2018).

Kemenkes RI, 2012. Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi

Antiretroviral pada Orang Dewasa dan Remaja. Direktorat Jenderal

Pengendalian Penyakit dan Penyehatan Lingkungan, Kementerian

Kesehatan RI, Jakarta.

Kemenkes RI, 2015. Peraturan Menteri Kesehatan Republik Indonesia Nomor 87

Tahun 2014 tentang Pedoman Pengobatan Antiretroviral. Kementerian

Kesehatan Republik Indonesia, Jakarta.

Kouotou, E.A., Nansseu, J.R., Ngono, V.N., Tatah, S.A., Zoung-Kanyi Bissek,

A.C., dan Ndjitoyap Ndam, E.C., 2017. Prevalence and Clinical Profile of

Drug Eruptions among Antiretroviral Therapy-Exposed HIV Infected

People in Yaoundé, Cameroon. Dermatology Research and Practice, 2017:

1–6.


115

KPAN, 2007. 'Strategi Nasional Penanggulangan HIV dan AIDS 2007-2010',

Yayasan Spiritia. URL: http://spiritia.or.id/dokumen/stranas07-10.pdf


KPAN, 2011. 'Rangkuman Eksekutif Upaya Penanggulangan HIV dan AIDS di

Indonesia 2006 - 2011: Laporan 5 Tahun Pelaksanaan Peraturan Presiden

No. 75/2006 tentang Komisi Penanggulangan AIDS Nasional', Komisi

Penanggulangan AIDS. URL:

http://www.aidsindonesia.or.id/repo/ExSumLap5thnInd.pdf (diakses

tanggal 4/4/2018).

KPAN, 2015. 'Strategi dan Rencana Aksi Nasional 2015-2019 Penanggulangan

HIV dan AIDS di Indonesia', Sistem Informasi HIV/AIDS&IMS Online

Kemenkes RI. URL:

siha.depkes.go.id/portal/files_upload/SRAN_2015_2019_FINAL.pdf


Li, H., Marley, G., Ma, W., Wei, C., Lackey, M., Ma, Q., dkk., 2016. The Role of

ARV Associated Adverse Drug Reactions in Influencing Adherence Among

HIV-Infected Individuals: A Systematic Review and Qualitative Meta-

Synthesis. AIDS and Behavior, 21: 341–351.

Li, M. dan Ramos, L.G., 2017. Drug-Induced QT Prolongation And Torsades de

Pointes. Pharmacovigilance Forum, 42: 473–477.

Lim, M.L., Min, S.S., Eron, J.J., Bertz, R.J., Robinson, M., Gaedigk, A., dkk., 2004.

Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-

Way Drug Interaction Through Cytochrome P-450 Induction. Journal of

Acquired Immune Deficiency Syndromes (1999), 36: 1034–1040.

Low, A., Gavriilidis, G., Larke, N., B-Lajoie, M.-R., Drouin, O., Stover, J., dkk.,

2016. Incidence of Opportunistic Infections and the Impact of Antiretroviral

Therapy Among HIV-Infected Adults in Low- and Middle-Income

Countries: A Systematic Review and Meta-analysis. Clinical Infectious

Diseases, 62: 1595–1603.

Luma, H.N., Doualla, M.-S., Choukem, S.-P., Temfack, E., Ashuntantang, G., Joko,

H.A., dkk., 2012. Adverse Drug Reactions of Highly Active Antiretroviral

Therapy (HAART) in HIV Infected Patients at the General Hospital,

Douala, Cameroon: A Cross Sectional Study. Pan African Medical Journal,

12: 1–7.

Manosuthi, W., Wiboonchutikul, S., dan Sungkanuparph, S., 2016. Integrated

Therapy for HIV and Tuberculosis. AIDS Research and Therapy, 13: 1–12.

Masenyetse, L.J., Manda, S., dan Mwambi, H.G., 2015. An Assessment of Adverse

Drug Reactions Among HIV Positive Patients Receiving Antiretroviral

Treatment in South Africa. AIDS Research and Therapy, 12: 6.

Mathis, S., Khanlari, B., Pulido, F., Schechter, M., Negredo, E., Nelson, M., dkk.,

2011. Effectiveness of Protease Inhibitor Monotherapy versus Combination

Antiretroviral Maintenance Therapy: A Meta-Analysis. PLoS ONE, 6:

e22003.

May, M.T., Vehreschild, J.-J., Trickey, A., Obel, N., Reiss, P., Bonnet, F., dkk.,

2016. Mortality According to CD4 Count at Start of Combination

Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15


116

Years After Start of Treatment: Collaborative Cohort Study. Clinical


Mayer, K.H. dan Hamilton, C.D., 2010. Synergistic Pandemics: Confronting the

Global HIV and Tuberculosis Epidemics. Clinical Infectious Diseases, 50:

S67–S70.

Mehta, U. dan Maartens, G., 2007. Is It Safe to Switch between Efavirenz and

Nevirapine in The Event of Toxicity? The Lancet Infectious Disease, 7:

733–738.

Moyle, G.J., Sabin, C.A., Cartledge, J., Johnson, M., Wilkins, E., Churchill, D.,

dkk., 2006. A Randomized Comparative Trial of Tenofovir DF or Abacavir

as Replacement for a Thymidine Analogue in Persons with Lipoatrophy.

AIDS, 20: 2043–2050.

Muhič, N., Mrhar, A., dan Brvar, M., 2017. Comparative Analysis of Three Drug–

Drug Interaction Screening Systems Against Probable Clinically Relevant

Drug–Drug Interactions: A Prospective Cohort Study. European Journal of

Clinical Pharmacology, 73: 875–882.

Nila, A., 2012. 'Evaluasi Kejadian Efek Samping Neuropati Perifer dan Lipodistrofi

pada Pasien HIV/AIDS yang Menggunakan Stavudin dalam Rejimen

Antiretroviral di Rumah Sakit Kanker Dharmais Jakarta', , Tesis, M. Farm.,

. Universitas Indonesia, Depok.

Nursalam dan Kurniawati, N.D., 2007. Asuhan Keperawatan Pada Pasien

Terinfeksi HIV/AIDS. Salemba Medika, Jakarta.

Nwabueze, S.A., Joe-Ikechebelu, N.N., Modebe, I.A., Adogu, P.O.U., dan Ele,

P.U., 2013. Relationship Between Peripheral Neuropathy and Antiretroviral

Drugs Used in the Management of Adult Human Immunodeficiency Virus

Patients. Journal of HIV & Human Reproduction, 1: 36–40.

Onyedum, C.C., Iroezindu, M.O., Chukwuka, C.J., Anyaene, C.E., Obi, F.I., dan

Young, E.E., 2013. Profile of HIV-infected Patients Receiving Second-line

Antiretroviral Therapy in a Resource-limited Setting in Nigeria.

Transactions of the Royal Society of Tropical Medicine and Hygiene, 107:

608–614.

Osinusi-Adekanmbi, O., Stafford, K., Ukpaka, A., Salami, D., Ajayi, S., Ndembi,

N., dkk., 2014a. Long-Term Outcome of Second-Line Antiretroviral

Therapy in Resource-Limited Settings. Journal of the International

Association of Providers of AIDS Care (JIAPAC), 13: 366–371.

Oumar, A.A., Diallo, K., Dembélé, J.P., Samaké, L., Sidibé, I., Togo, B., dkk.,

2012. Adverse Drug Reactions to Antiretroviral Therapy: Prospective Study

in Children in Sikasso (Mali). The Journal of Pediatric Pharmacology and

Therapeutics, 17: 382–388.

Palombi, L., Marazzi, M.C., Guidotti, G., Germano, P., Buonomo, E., Scarcella, P.,

dkk., 2009. Incidence and Predictors of Death, Retention, and Switch to

Second‐Line Regimens in Antiretroviral‐Treated Patients in Sub‐Saharan

African Sites with Comprehensive Monitoring Availability. Clinical



117

Panel on Antiretroviral Guidelines for Adults and Adolescents, 2017. Guidelines

for the Use of Antiretroviral Agents in Adults and Adolescents Living with

HIV. Department of Health and Human Services.

Patel, D., Desai, M., Shah, A.N., dan Dikshit, R.K., 2013. Early Outcome of Second

Line Antiretroviral Therapy in Treatment-Experienced Human

Immunodeficiency Virus Positive Patients. Perspectives in Clinical

Research, 4: 215–220.

Paton, N.I., Kityo, C., Hoppe, A., Reid, A., Kambugu, A., Lugemwa, A., dkk.,

2014. Assessment of Second-Line Antiretroviral Regimens for HIV

Therapy in Africa. New England Journal of Medicine, 371: 234–247.

Perwira, I., 2015. 'Profilaksis Pra Pajanan (PPrP) sebagai Alternatif Pencegahan

Penularan HIV', Kebijakan AIDS Indonesia. URL:

http://www.kebijakanaidsindonesia.net/id/artikel/artikel-tematik/1378-

profilaksis-pra-pajanan-pprp-sebagai-alternatif-pencegahan-penularan-hiv


Pettersen, J.A., Jones, G., Worthington, C., Krentz, H.B., Keppler, O.T., Hoke, A.,

dkk., 2006. Sensory Neuropathy in Human Immunodeficiency

Virus/Acquired Immunodeficiency Syndrome Patients: Protease Inhibitor–

Mediated Neurotoxicity. Annals of Neurology, 59: 816–824.

Pirmohamed, M., Atuah, K.N., Dodoo, A.N.O., dan Winstanley, P., 2007.

Pharmacovigilance in Developing Countries. BMJ, 335: 462–462.

Pokala, N., Dixit, R., Manubhai, P.M., dan Vijayal, K., 2014. Adverse Drug

Reactions with Second Line Antiretroviral Drug Regimen. Asian Journal of

Pharmaceutical and Clinical Research, 7: 75–79.

Prasitsuebsai, W., Teeraananchai, S., Singtoroj, T., Truong, K.H., Ananworanich,

J., Do, V.C., dkk., 2016. Treatment Outcomes and Resistance Patterns of

Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.

Journal of Acquired Immune Deficiency Syndromes (1999), 72: 380–386.

Preston, C.L., Elaina E Crehan, Driver, S., Hatwal, C.S., Jones, S.L., Khan, S.Z.,

dkk., 2014. Stockley’s Drug Interactions Pocket Companion 2015.

Pharmaceutical Press, London.

Pujades-Rodríguez, M., Balkan, S., Arnould, L., Brinkhof, M.A.W., dan Calmy, A.,

2010. Treatment Failure and Mortality Factors in Patients Receiving

Second-Line HIV Therapy in Resource-Limited Countries. JAMA, 304:

303.

Pusdatin Kemenkes RI, 2016. Situasi Penyakit HIV/AIDS Di Indonesia.

InfoDATIN, Pusat Data dan Informasi Kementerian Kesehatan RI, Jakarta.

Raffi, F., Babiker, A.G., Richert, L., Molina, J.-M., George, E.C., Antinori, A.,

dkk., 2014. Ritonavir-Boosted Darunavir Combined with Raltegravir or

Tenofovir–Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-

1: 96 Week Results from the NEAT001/ANRS143 Randomised Non-

Inferiority Trial. The Lancet, 384: 1942–1951.

Ramadhani, H.O., Bartlett, J.A., Thielman, N.M., Pence, B.W., Kimani, S.M.,

Maro, V.P., dkk., 2014. Association of First-Line and Second-Line

Antiretroviral Therapy Adherence. Open Forum Infectious Diseases, 1:

ofu079–ofu079.


118

Ramadhani, H.O., Bartlett, J.A., Thielman, N.M., Pence, B.W., Kimani, S.M.,

Maro, V.P., dkk., 2016. The Effect of Switching to Second-Line

Antiretroviral Therapy on the Risk of Opportunistic Infections among

Patients Infected with Human Immunodeficiency Virus in Northern

Tanzania. Open Forum Infectious Diseases, 3: ofw018.

Reynes, J., Lawal, A., Pulido, F., Soto-Malave, R., Gathe, J., Tian, M., dkk., 2011.

Examination of Noninferiority, Safety, and Tolerability of

Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and

Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The

PROGRESS Study, 48-Week Results. HIV Clinical Trials, 12: 255–267.

Reynes, J., Trinh, R., Pulido, F., Soto-Malave, R., Gathe, J., Qaqish, R., dkk., 2012.

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine

in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS

Study. AIDS Research and Human Retroviruses, 120803082830003.

Sattler, F.R., 2008. Pathogenesis and Treatment of Lipodystrophy : What Clinicians

Need to Know. Topics in HIV Medicine, 16: 127–133.

Sears, D.W., 2009. 'Structure of HIV', Biosci Portal. URL:

https://biosci.mcdb.ucsb.edu/immunology/Immunodeficiencies/HIV-

structure.htm (diakses tanggal 21/3/2017).

Shet, A., Antony, J., Arumugam, K., Kumar Dodderi, S., Rodrigues, R., dan

DeCosta, A., 2014. Influence of Adverse Drug Reactions on Treatment

Success: Prospective Cohort Analysis of HIV-Infected Individuals

Initiating First-Line Antiretroviral Therapy in India. PLoS ONE, 9: e91028.

Soorju, V. dan Naidoo, P., 2016. Confirmation of Factors That Influence

Antiretroviral Regimen Change and the Subsequent Patient Outcomes at a

Regional Hospital in Rural Kwazulu-Natal. African Journal of Primary

Health Care & Family Medicine, 8: 1–6.

Ssempijja, V., Nakigozi, G., Chang, L., Gray, R., Wawer, M., Ndyanabo, A., dkk.,

2017. Rates of Switching to Second-Line Antiretroviral Therapy and Impact

of Delayed Switching on Immunologic, Virologic, and Mortality Outcomes

Among HIV-Infected Adults with Virologic Failure in Rakai, Uganda. BMC


Stockdale, A.J., Saunders, M.J., Boyd, M.A., Bonnett, L.J., Johnston, V., Wandeler,

G., dkk., 2017. Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse

Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the

Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-

Saharan Africa: A Systematic Review and Meta-analysis. Clinical

Infectious Diseases, XX: 1–12.

Sugiharti, S., Yuniar, Y., dan Lestary, H., 2014. Gambaran Kepatuhan Orang

dengan HIV/AIDS (ODHA) dalam Minum Obat ARV di Kota Bandung,

Provinsi Jawa Barat, Tahun 2011-2012. Jurnal Kesehatan Reproduksi, 5:

11.

Sunpath, H., Winternheimer, P., Cohen, S., Tennant, I., Chelin, N., Gandhi, R.T.,

dkk., 2014. Double-Dose Lopinavir-Ritonavir in Combination with

Rifampicin-Based Anti-Tuberculosis Treatment in South Africa. The

International Journal of Tuberculosis and Lung Disease: The Official


119

Journal of the International Union Against Tuberculosis and Lung Disease,

18: 689–693.

Tambunan, R., Kamil, O., Praptoraharjo, I., Erlan, H., dan Irwanto, 2010. 'Jaringan

Seksual dan Penggunaan NAPZA pada Pengguna NAPZA Suntik di 6

Propinsi', Komisi Penanggulangan AIDS. URL:

www.aidsindonesia.or.id/repo/perpustakaan/jaringanseksidu.pdf (diakses

tanggal 4/4/2018).

Thao, V.P., Quang, V.M., Wolbers, M., Anh, N.D., Shikuma, C., Farrar, J., dkk.,

2015. Second-Line HIV Therapy Outcomes and Determinants of Mortality

at the Largest HIV Referral Center in Southern Vietnam. Medicine, 94:

e1715.

Tisdale, J.E., 2016. Drug-Induced Qt Interval Prolongation and Torsades De

Pointes. Canadian Pharmacists Journal : CPJ, 149: 139–152.

Truven Health Analytics, 2011. 'Lopinavir/ritonavir', DynaMed Plus. URL:

http://www.dynamed.com/topics/dmp~AN~T232794/Lopinavir-

Ritonavir#Drug-Interactions (diakses tanggal 12/3/2018).

Tsegaye, A.T., Wubshet, M., Awoke, T., dan Addis Alene, K., 2016. Predictors of

Treatment Failure on Second-Line Antiretroviral Therapy Among Adults in

Northwest Ethiopia: A Multicentre Retrospective Follow-up Study. BMJ

Open, 6: e012537.

UNAIDS, 2016a. 'Global AIDS Update 2016', UNAIDS. URL:

http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-

2016_en.pdf (diakses tanggal 28/3/2018).

UNAIDS, 2016b. 'AIDS by the Numbers, AIDS is Not Over, but It Can Be', . URL:

http://www.unaids.org/sites/default/files/media_asset/AIDS-by-the-

numbers-2016_en.pdf (diakses tanggal 28/3/2018).

UNAIDS, 2016c. 'Country Factsheets Indonesia 2016', AIDSinfo. URL:

http://aidsinfo.unaids.org/ (diakses tanggal 28/3/2018).

Vadlapatla, R.K., Patel, M., Paturi, D.K., Pal, D., dan Mitra, A.K., 2014. Clinically

Relevant Drug–Drug Interactions Between Antiretrovirals and Antifungals.

Expert Opinion on Drug Metabolism & Toxicology, 10: 561–580.

Wandeler, G., Rohr, J., Chi, B.H., Orrell, C., Chimbetete, C., Prozesky, H., dkk.,

2014. Tenofovir or Zidovudine in Second-Line Antiretroviral Therapy After

Stavudine Failure in Southern Africa. Antiviral Therapy, 19: 521–525.

WHO, 2013a. Consolidated Guidelines on the Use of Antiretroviral Drugs for

Treating and Preventing HIV Infection: Recommendations for a Public

Health Approach. World Health Organization, Geneva, Switzerland.

WHO, 2013b. 'Summary of Key ARV Drug Interactions', World Health

Organization. URL:

http://apps.who.int/iris/bitstream/10665/91047/1/WHO_HIV_2013.66_eng

.pdf?ua=1 (diakses tanggal 3/12/2018).

WHO, 2013c. 'How Accurately Do the WHO 2010 Immunological or Clinical

Criteria Predict Virological Failure in Adults and Children Receiving

ART?', World Health Organization. URL:

http://apps.who.int/iris/bitstream/handle/10665/91031/WHO_HIV_2013.4

3_eng.pdf?sequence=1 (diakses tanggal 4/4/2018).


120

Winarno, H., Suryoputro, A., dan Shaluhiyah, Z., 2008. Faktor-Faktor yang

Berhubungan dengan Penggunaan Jarum Suntik Bergantian di antara

Pengguna NAPZA Suntik di Kota Semarang. Jurnal Promosi Kesehatan

Indonesia, 3: 74–85.

Yasin, N.M., Maranty, H., dan Ningsih, W.R., 2011. Analisis Respon Terapi

Antiretroviral pada Pasien HIV/AIDS. Majalah Farmasi Indonesia, 22:

212–222.


WINDA DWI P., Dr. Nanang Munif Yasin, M.Pharm., Apt.; Dr ...

Documents

Transcript of WINDA DWI P., Dr. Nanang Munif Yasin, M.Pharm., Apt.; Dr ...